Higher circulating anti-Müllerian hormone (AMH) levels are associated with increased breast cancer risk among premenopausal women, according to a study of blood samples from 62,437 women, including 539 who were later diagnosed with breast cancer and 539 matched controls. Researchers found:
• Higher plasma levels of AMH were associated with increased breast cancer risk (top vs bottom quintile OR=2.20).
• This association did not vary by invasive vs in situ disease or by estrogen receptor status.
• Associations were not significantly different by age at blood sampling or at diagnosis.
• Additional adjustment for plasma estradiol or testosterone yielded similar results.
Citation: Eliassen AH, Zeleniuch-Jacquotte A, Rosner B, Hankinson SE. Plasma anti-Müllerian hormone concentrations and risk of breast cancer among premenopausal women in the Nurses' Health Studies. [Published online ahead of print March 9, 2016]. Cancer Epidemiol Biomarkers Prev. doi:10.1158/1055-9965.EPI-15-1240.
This Week's Must Reads
Must Reads in Breast Cancer
Gender Images & Social Expectations in BC Diagnosis, Cancer; ePub 2018 Sep 24; Kim, Glassgow, et al
Predicting Mammography Adherence by Income Level, Women’s Health Issues; ePub 2018 Aug 8; Gathirua-Mwangi, et al
Estrogen-alone Therapy & Invasive Breast Cancer, Menopause; ePub 2018 May 7; Shufelt, et al
Missed Breast Cancers in High Risk MRI Screening, Breast Cancer Res Treat; ePub 2018 Jan 31; Vreemann, et al